December 7-8, 2026
Hilton La Jolla Torrey PinesLa Jolla, CAAlign Medicaid, Commercial & Government Teams to Deliver Market-Leading Results
Unite with best-in-class industry leaders from established and emerging pharma/bio manufacturers, government regulators and additional stakeholders to tackle the complex regulatory and operational challenges related to IRA, MFN, MFP, 340B, Medicaid, State Drug Price Transparency and more!
Experience all the latest in pricing and contracting for life sciences
With insights gained from our vibrant pricing and contracting community, we're primed for another ground-breaking event - this time we're HEADED WEST! Whether you're a seasoned pro or a newcomer, get ready for an upgraded program packed with cutting-edge topics such as Medicaid, Government Pricing and Policy, Drug Price Transparency, 340B, IRA, MFN, MFP and more.
Don't just take our word for it — check out the thrilling preview of what's to come in 2026 in La Jolla, California!
Decode Policy Complexity into Operational Action with Government & Industry Leadership
- Gain direct insights from CMS leadership on IRA implementation, MFN/MFP execution, and 340B reform—understanding what policy developments mean for your day-to-day operations
- Navigate overlapping regulatory demands through practical strategies for MFN/MFP preparation, state transparency compliance, and ASP calculation under evolving bona fide service fee guidance
- Hear PhRMA's outlook on the legal and regulatory developments reshaping manufacturer strategy over the next 12-18 months
- Bridge the gap between policy design and implementation realities with cross-functional alignment strategies for government pricing, commercial contracting, finance, and legal teams managing AMP, Best Price, and GTN relationships
Transform Market Pressures into Strategic Advantage Through Cross-Functional Excellence
- Address the growing relationship between gross-to-net dynamics, PBM economics, and government pricing obligations—understanding why more revenue doesn't always mean more profitability
- Develop practical approaches to 340B duplicate discount challenges, revenue leakage mitigation, and alternative rebate model pilot programs
- Navigate the unique pricing, contracting, and government reporting considerations for cell & gene therapies, including outcomes-based agreements and innovative reimbursement models
- Explore how AI is moving from experimentation to practical application in contract analytics, rebate validation, state transparency monitoring, and compliance review
- Understand the future of formulary management and PBM economics as policymakers scrutinize rebate practices and pass-through models
Access Peer Intelligence and Build Strategic Relationships That Drive Results
- Participate in Director-level and above closed-door Leadership Exchange Roundtables on 340B reform & duplicate discounts, MFN/MFP readiness, Medicaid disputes & state variability, and government pricing leadership challenges
- Gain rare perspectives from current and former State Medicaid Directors on the operational realities, constraints, and priorities shaping program decision-making—understanding why states make certain operational decisions
- Learn from state representatives and affordability review bodies about factors beyond cost that influence drug value assessments and best practices for manufacturer engagement
- Connect with government pricing executives, market access leaders, and policy experts through dedicated networking breaks, luncheons, and an evening reception
- Engage in peer-to-peer problem-solving with leaders facing the same operational challenges: commercial-government alignment, resource allocation amid regulatory complexity, and preparing leadership teams for long-term impacts
